You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK):與京東健康簽署框架協議
格隆匯 06-28 22:02

格隆匯 6 月 28日丨開拓藥業-B(09939.HK)公佈,2020年6月20日,公司全資子公司蘇州開拓藥業股份有限公司與北京京東健康有限公司(“京東健康”)簽署框架協議。根據框架協議,雙方將就福瑞他恩(KX-826)在京東健康運營的線上藥品零售平台yiyaojd.com(“京東大藥房”)的銷售展開深入合作。

京東健康是京東集團股份有限公司旗下一家依據中華人民共和國法律設立的子公司。京東集團股份有限公司是中國領先的技術驅動型電子商務運營商和零售基礎設施提供商,在香港聯交所(股票代碼:9618)和納斯達克交易所(股票代碼:JD)雙地上市。京東大藥房是中國最大的零售藥店,擁有強大的網絡運營和營銷能力。目前,京東大藥房在全國範圍內現有七座倉庫,全部位於中國的核心城市,並採用專有的智能物流和自動化技術,確保京東大藥房以行業領先的效率運營。京東大藥房憑藉其集團領先的大數據、人工智能和零售技術,為藥品提供線上營銷的一體化解決方案,為業界夥伴提供綜合的價值創造,賦能醫藥產業鏈。京東大藥房的零售模式致力於構建專業及值得信賴的醫療服務體系,從而不斷提升藥品的可及性和患者依從性。

福瑞他恩是一種外用的AR拮抗劑,它直接作用於頭皮的目標治療部位。福瑞他恩正在進行中國的II期臨牀試驗和美國的Ib期臨牀試驗。和京東健康基於該框架協議的合作將提高集團在商業零售渠道的能力,從而為雙方創造互惠互利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account